DON LYNN GIBBONS to Piperazines
This is a "connection" page, showing publications DON LYNN GIBBONS has written about Piperazines.
Connection Strength
0.209
-
CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. Cancer Res. 2017 07 15; 77(14):3870-3884.
Score: 0.076
-
Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy. Proc Natl Acad Sci U S A. 2014 Mar 04; 111(9):3550-5.
Score: 0.061
-
The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm. Cancer. 2012 Jan 15; 118(2):293-9.
Score: 0.051
-
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. Cancer Discov. 2019 05; 9(5):646-661.
Score: 0.022